GUT1 Antibody

What is GLUT1 and what is its biological significance?

GLUT1 (Glucose Transporter 1), also known as solute carrier family 2 member 1 (SLC2A1), is a uniporter protein responsible for transporting glucose across cellular membranes. It plays critical roles in:

• Constitutive or basal glucose uptake in most cells

• Glucose transport across the blood-brain barrier

• Energy provision in erythrocytes

• Retinal cone survival (in association with BSG and NXNL1)

• Mesendoderm differentiation

GLUT1 has a broad substrate specificity, capable of transporting various aldoses including pentoses and hexoses, as well as oxidized ascorbic acid (vitamin C) . It's particularly important as the primary energy carrier in the brain, facilitating energy-independent, facilitative transport of glucose into neural tissue .

What is the molecular weight of GLUT1 and why does it sometimes appear at different weights in Western blots?

GLUT1 has a calculated molecular weight of approximately 54 kDa (492 amino acids) , but it commonly appears at different molecular weights in experimental settings:

This variability is primarily due to post-translational modifications, particularly N-glycosylation of asparagine at position 42, which is the only known post-translational modification of GLUT1 . Sample preparation can also affect observed molecular weight - avoiding boiling after lysis may be recommended for optimal detection with certain antibodies .

What is the tissue distribution pattern of GLUT1?

GLUT1 expression varies widely across tissues, with expression levels correlating with glucose metabolism rates:

In normal brain tissue, GLUT1 shows strong endothelial staining of vessels but is negative in other brain structures . This specific expression pattern makes GLUT1 a useful marker for endothelial cells in the central nervous system.

What are the validated applications for GLUT1 antibodies in research?

GLUT1 antibodies have been validated for numerous research applications:

When selecting an antibody, researchers should verify specificity and reactivity with their target species. Many GLUT1 antibodies cross-react with multiple species due to high sequence conservation .

How should samples be prepared for optimal GLUT1 detection in Western blots?

Sample preparation significantly impacts GLUT1 detection in Western blotting:

• Lysis conditions: For some antibodies (e.g., 21829-1-AP), avoid boiling samples after lysis to prevent protein aggregation .

• Buffer selection: Use appropriate buffer systems:

  • Immunoblot Buffer Group 1 has been validated for GLUT1 detection with MAB14181

  • PVDF membranes are recommended over nitrocellulose for many GLUT1 antibodies

• Reduction conditions: Most protocols use reducing conditions which can affect the observed molecular weight .

• Positive controls: Use validated cell lines such as:

  • A431 human epithelial carcinoma cells

  • HepG2 human hepatocellular carcinoma cells

  • Jurkat human T cell leukemia cells

• Protein loading: 0.2-0.5 mg/mL protein concentration is typically sufficient for detection .

What are the optimal conditions for immunostaining with GLUT1 antibodies?

For successful immunostaining, consider the following parameters:

For IHC:

• Antigen retrieval: TE buffer pH 9.0 is recommended; alternatively, citrate buffer pH 6.0 can be used

• Dilution range: 1:100-1:10000 depending on the antibody and tissue

• Positive controls: Brain tissue (endothelial cells should show strong GLUT1 staining)

• Negative controls: Brain tissue (GLUT1 staining should be absent in all cells except blood vessels)

For IF/ICC:

• Fixation: Immersion fixation works well for cultured cells

• Dilution: 1:200-1:800 is typically effective

• Counterstaining: DAPI for nuclear visualization

• Subcellular localization: GLUT1 should localize primarily to plasma membranes

How can GLUT1 antibodies be used to study GLUT1 deficiency syndrome (Glut1 DS)?

GLUT1 deficiency syndrome (Glut1 DS) is a genetic disorder caused by mutations in the SLC2A1 gene. Researchers can utilize GLUT1 antibodies to:

• Quantify GLUT1 expression levels in patient-derived samples or animal models

• Investigate brain angiogenesis defects:

  • GLUT1 functions in cerebral microvasculature affecting endothelial tip cells

  • Brain endothelial cell-specific GLUT1 depletion triggers neuroinflammation

  • Neonatal GLUT1 depletion arrests brain angiogenesis and causes the most severe pathology

• Assess therapeutic interventions:

  • Early repletion of GLUT1 protein can avert brain microvasculature defects

  • Monitor GLUT1 restoration in treatment studies

  • Temporal studies show greatest efficacy when implemented in the first postnatal week

• Study molecular mechanisms:

  • GLUT1 deficiency reduces brain-derived neurotrophic factor (BDNF) levels

  • BDNF reduction correlates with neuronal loss in the Glut1 DS brain

  • Investigate cell-autonomous effects in the cerebral microvasculature

How can GLUT1 antibodies be used to investigate the role of glucose metabolism in immune cell function?

GLUT1 antibodies have revealed critical insights into immunometabolism:

• T cell activation and differentiation:

  • Flow cytometry with GLUT1 antibodies (e.g., MAB1418) can measure GLUT1 upregulation during T cell activation

  • GLUT1 expression increases in T cells cultured in nutrient-depleted media, reflecting metabolic adaptation

• Chronic stimulation effects:

  • GLUT1 antibodies can assess metabolic changes during chronic immune stimulation

  • Flow cytometry analysis reveals how receptor-mediated signals alter glucose uptake

• Metabolic programming in different T cell subsets:

  • GLUT1 antibodies help distinguish metabolic profiles between naïve, memory, and effector T cells

  • Research shows alcohol impairs immunometabolism and promotes naïve T cell differentiation to pro-inflammatory Th1 CD4+ T cells

• HIV infection studies:

  • GLUT1 antibodies have demonstrated that HIV-1 infection induces HIF-1α in CD4+ T cells

  • This promotes viral replication and drives extracellular vesicle-mediated inflammation

  • Flow cytometry with GLUT1 antibodies can assess metabolic dynamics in virologically suppressed HIV-positive individuals

What approaches are being used to enhance antibody affinity through experimental sampling?

Recent research has focused on optimizing antibody affinity through various methods:

• Machine learning (ML) approaches:

  • AbRFC (a machine learning model) has been developed to discover affinity-enhancing mutations

  • This enables experimental sampling of non-deleterious mutations to enhance antibody binding

• Experimental workflow integration:

  • ML models combined with iterative experimental optimization can increase antibody affinity by 50-fold

  • AbRFC has successfully enhanced two distinct template antibodies that had lost affinity to SARS-CoV-2 Omicron variants

  • This approach achieved >1000-fold improved affinity against various Omicron subvariants (BA.1, BA.2, BA.4/5)

• Feature engineering approaches:

  • Expert-engineered features designed for small datasets can outperform deep learning in certain contexts

  • 5-fold cross-validation optimizes hyperparameters and increases model regularization

  • Testing on out-of-distribution validation datasets ensures model generalizability

• Polyreactivity screening:

  • Screening for polyreactivity helps predict successful progression through late-stage development

  • Strong polyreactivity profiles represent risk factors that could increase failure likelihood in clinical development

  • This has provided insights into high-profile clinical development failures like bococizumab

How can researchers validate the specificity of GLUT1 antibodies?

Validating antibody specificity is crucial for reliable research outcomes:

• Knockout validation:

  • Use SLC2A1 knockout cell lines to confirm antibody specificity

  • Absence of signal in knockout samples confirms target specificity

• Multi-tissue microarray (TMA) validation:

  • Test antibodies against multiple tissue types to verify expected expression patterns

  • GLUT1 should show strong endothelial staining in brain vasculature but be negative in most other brain cells

• Appropriate controls:

  • Positive controls: A431 cells, HepG2 cells, brain endothelial cells

  • Negative controls: Isotype control antibodies (e.g., MAB0041 for mouse antibodies)

  • Pre-immune serum control comparisons

• Peptide blocking:

  • Use synthetic peptides corresponding to the immunogen sequence

  • For example, PEP-289 peptide can neutralize PA1-1063 antibody binding

• Multiple detection methods:

  • Compare results across different applications (WB, IHC, FC)

  • Concordance across methods increases confidence in specificity

What are common troubleshooting strategies for GLUT1 antibody applications?

When encountering issues with GLUT1 detection, consider these troubleshooting approaches:

• Western blot issues:

  • Non-specific bands at ~230 kDa may appear in Simple Western systems with certain antibodies

  • Avoid boiling samples after lysis for optimal detection with some antibodies (e.g., 21829-1-AP)

  • Use appropriate buffer systems (Immunoblot Buffer Group 1 recommended for some antibodies)

• Flow cytometry optimization:

  • For intracellular GLUT1, use approximately 0.40 μg antibody per 10^6 cells in 100 μl suspension

  • Compare untreated cells versus those cultured in nutrient-depleted media as a functional control

  • Suitable secondary antibodies include Allophycocyanin-conjugated or Phycoerythrin-conjugated Anti-Mouse IgG

• Immunostaining problems:

  • For weak signal in IHC, try TE buffer pH 9.0 for antigen retrieval

  • Use freshly prepared fixatives and avoid freeze-thaw cycles of antibodies

  • For membrane localization, ensure samples are properly fixed to preserve membrane structures

• Storage and handling:

  • Avoid repeated freeze-thaw cycles

  • Store most GLUT1 antibodies at -20°C to -70°C for long-term storage

  • For reconstituted antibodies, store at 2-8°C under sterile conditions for up to 1 month

How are GLUT1 antibodies being used in cancer research and potential therapeutic development?

GLUT1 is emerging as an important target in cancer research:

• Cancer progression biomarker:

  • GLUT1 overexpression has been linked to tumor progression and poor survival in carcinomas of the colon, breast, cervix, lung, bladder, and mesothelioma

  • GLUT1 serves as a sensitive and specific marker for differentiating malignant mesothelioma (positive) from reactive mesothelium (negative)

• Metabolic reprogramming insights:

  • Many tumors undergo a metabolic switch from oxidative phosphorylation to glycolysis

  • This "Warburg effect" requires elevated glucose uptake, often facilitated by GLUT1 upregulation

  • GLUT1 antibodies can identify tumors with this metabolic phenotype

• Therapeutic targeting:

  • GLUT1 represents a potential therapeutic target for inhibitors such as Bay-876

  • Antibodies are used to validate target engagement in drug development

  • Monitoring changes in GLUT1 expression can assess treatment efficacy

• Single-cell analysis approaches:

  • Mass cytometry combined with GLUT1 antibodies reveals complexity of non-small cell lung cancer cells

  • This approach has demonstrated differences between in vivo and three-dimensional models compared to traditional Petri-dish cultures

What emerging applications are being developed for GLUT1 antibodies in neuroscience research?

Neuroscience applications for GLUT1 antibodies are expanding:

• Blood-brain barrier (BBB) integrity:

  • GLUT1 antibodies can assess BBB integrity and function in various neurological conditions

  • Temporal requirements for GLUT1 in brain development can be studied using controlled depletion models

• Neuroinflammatory responses:

  • Brain endothelial cell-specific GLUT1 depletion triggers severe neuroinflammatory responses

  • GLUT1 antibodies can track this process and its relationship to disease progression

• Alzheimer's disease research:

  • GLUT1 antibodies help investigate the relationship between glucose metabolism and amyloid-beta toxicity

  • Studies have shown dendritic functions of tau mediate amyloid-beta toxicity in Alzheimer's disease mouse models

• Cerebral angiogenesis:

  • Controlled depletion of GLUT1 in neonatal mice arrests brain angiogenesis

  • This provides insights into developmental disorders and potential therapeutic windows

  • GLUT1 antibodies enable visualization of these vascular changes